ANIP|ANI Pharmaceuticals Inc|Price:78.010|Chg%:-1.57

More Details of ANI Pharmaceuticals Inc Company

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

ANI Pharmaceuticals Inc Info



Ticker SymbolANIP

Company nameANI Pharmaceuticals Inc

IPO dateMay 04, 2000

CEOLalwani (Nikhil Suresh)

Number of employees897

Security typeOrdinary Share

Fiscal year-endMay 04

Address210 Main Street West

CityBAUDETTE

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code56623

Phone12186343500

Websitehttps://www.anipharmaceuticals.com/

Ticker SymbolANIP

IPO dateMay 04, 2000

CEOLalwani (Nikhil Suresh)

Company Executives of ANI Pharmaceuticals Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Chad Gassert

Senior Vice President - Corporate Development and Strategy

311.43K

+0.42%

Mr. Nikhil Suresh Lalwani

President, Chief Executive Officer, Director

290.27K

-45.36%

Mr. Muthusamy Shanmugam

Director, Head of Research and Development, Chief Operating Officer - Novitium Operations

82.54K

-22.14%

Mr. Ori Gutwerg

Senior Vice President - Generics

61.18K

-41.94%

Mr. Patrick D. Walsh

Independent Chairman of the Board

52.41K

-11.45%

Ms. Krista Davis

Chief Human Resources Officer, Senior Vice President

51.95K

-12.65%

Mr. Thomas Andrew (Thom) Rowland

Senior Vice President, Head of Established Brands

37.85K

-12.61%

Mr. Thomas J. (Tom) Haughey, J.D.

Independent Director

36.52K

--

Dr. Renee P. Tannenbaum, Pharm.D.

Independent Director

25.16K

--

Mr. Matthew J. (Matt) Leonard

Independent Director

6.86K

--

Name

Name/Position

Position

Shareholding

Change

Mr. Chad Gassert

Senior Vice President - Corporate Development and Strategy

311.43K

+0.42%

Mr. Nikhil Suresh Lalwani

President, Chief Executive Officer, Director

290.27K

-45.36%

Mr. Muthusamy Shanmugam

Director, Head of Research and Development, Chief Operating Officer - Novitium Operations

82.54K

-22.14%

Mr. Ori Gutwerg

Senior Vice President - Generics

61.18K

-41.94%

Mr. Patrick D. Walsh

Independent Chairman of the Board

52.41K

-11.45%

Ms. Krista Davis

Chief Human Resources Officer, Senior Vice President

51.95K

-12.65%

Revenue Breakdown

Currency: USDUpdated: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

Sales of generic pharmaceutical products

384.11M

43.48%

Sales of rare disease pharmaceutical products

347.78M

39.37%

Sales of Cortrophin Gel

347.78M

39.37%

Sales of branded pharmaceutical products

76.61M

8.67%

By RegionUSD

Name

Revenue

Proportion

United States

852.44M

96.50%

International

30.92M

3.50%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Sales of generic pharmaceutical products

384.11M

43.48%

Sales of rare disease pharmaceutical products

347.78M

39.37%

Sales of Cortrophin Gel

347.78M

39.37%

Sales of branded pharmaceutical products

76.61M

8.67%

Shareholding Stats

Updated: Sun, May 10

Shareholders

Shareholder Types

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

10.76%

Meridian Venture Partners

4.46%

Vanguard Capital Management, LLC

3.62%

State Street Investment Management (US)

3.20%

Millennium Management LLC

2.37%

Other

75.58%

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

10.76%

Meridian Venture Partners

4.46%

Vanguard Capital Management, LLC

3.62%

State Street Investment Management (US)

3.20%

Millennium Management LLC

2.37%

Other

75.58%

Shareholder Types

Shareholders

Proportion

Investment Advisor

42.89%

Investment Advisor/Hedge Fund

23.64%

Hedge Fund

20.43%

Research Firm

6.41%

Individual Investor

5.68%

Private Equity

4.46%

Pension Fund

2.51%

Corporation

1.92%

Bank and Trust

1.50%

Institutional Shareholding



Updated: Wed, Apr 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q1

555

23.15M

101.74%

+57.73K

2025Q4

507

21.97M

100.49%

+14.84K

2025Q3

525

21.96M

103.27%

+407.79K

2025Q2

506

21.46M

110.44%

-446.10K

2025Q1

489

21.61M

106.49%

-1.37M

2024Q4

469

21.12M

108.93%

+156.97K

2024Q3

453

20.75M

88.54%

+3.60M

2024Q2

425

17.36M

85.19%

+1.07M

2024Q1

403

16.22M

82.13%

-1.01M

2023Q4

390

16.10M

82.95%

+39.70K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

BlackRock Institutional Trust Company, N.A.

2.45M

10.91%

+103.61K

+4.42%

Dec 31, 2025

Meridian Venture Partners

1.01M

4.53%

-150.00K

-12.88%

Aug 21, 2025

State Street Investment Management (US)

727.20K

3.24%

+15.50K

+2.18%

Dec 31, 2025

Millennium Management LLC

539.66K

2.41%

+474.42K

+727.14%

Dec 31, 2025

Dimensional Fund Advisors, L.P.

487.67K

2.18%

-17.76K

-3.51%

Dec 31, 2025

Soleus Capital Management, L.P.

486.24K

2.17%

+146.00K

+42.91%

Dec 31, 2025

Tang Capital Management, LLC

481.44K

2.15%

+163.94K

+51.63%

Dec 31, 2025

Deep Track Capital LP

477.68K

2.13%

+27.68K

+6.15%

Dec 31, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

Invesco Pharmaceuticals ETF

2.63%

State Street SPDR S&P Pharmaceuticals ETF

2.42%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.95%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.63%

Innovator IBD Breakout Opportunities ETF

1.38%

Innovator IBD 50 Fund ETF

1.02%

Invesco Dorsey Wright Healthcare Momentum ETF

0.98%

Invesco S&P SmallCap Health Care ETF

0.96%

Janus Henderson Small/Mid Cap Growth Alpha ETF

0.92%

First Trust Small Cap Growth AlphaDEX Fund

0.67%

Invesco Pharmaceuticals ETF

Proportion2.63%

State Street SPDR S&P Pharmaceuticals ETF

Proportion2.42%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proportion1.95%

Pacer US Small Cap Cash Cows Growth Leaders ETF

Proportion1.63%

Innovator IBD Breakout Opportunities ETF

Proportion1.38%

Innovator IBD 50 Fund ETF

Proportion1.02%

Invesco Dorsey Wright Healthcare Momentum ETF

Proportion0.98%

Invesco S&P SmallCap Health Care ETF

Proportion0.96%

Janus Henderson Small/Mid Cap Growth Alpha ETF

Proportion0.92%

First Trust Small Cap Growth AlphaDEX Fund

Proportion0.67%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data